Overview Request Sample Pages Request Customization Download PDF
You are viewing: Italy Preimplantation Genetic Testing Market analysis

The Italy Preimplantation Genetic Testing Market was valued at $8.9 Million in 2025 and projected to reach to $14.3 Million by 2030, representing a compound annual growth rate of 9.8%. Italy's preimplantation genetic testing market is positioned for steady growth, driven by increasing adoption of assisted reproductive technologies and rising patient demand for genetic screening.

Italy Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Italy Preimplantation Genetic Testing Market Trends and Insights

  • This growth trajectory reflects Italy's increasing adoption of advanced reproductive technologies and heightened awareness among fertility clinics and patients regarding genetic screening benefits.
  • Italy's healthcare infrastructure and regulatory environment continue to support the integration of PGT into assisted reproductive procedures, driving market penetration across major metropolitan regions. The Italian market benefits from rising demand for early genetic disease detection and improved embryo selection outcomes.
  • Between 2025 and 2030, Italy is expected to witness accelerated investment in fertility centers equipped with PGT capabilities, supported by growing patient education and clinical evidence.
  • Italy's aging population and declining birth rates further incentivize adoption of PGT technologies to optimize reproductive success rates and reduce genetic disorder transmission..

Key Market Statistics

  • CAGR (2025-2030) 9.8% CAGR
  • Market Size, 2025 ~USD 8.9 Million
  • Forecast, 2030 ~USD 14.3 Million
  • Country Italy

Italy Preimplantation Genetic Testing Market Overview

Market Valuation Growth :

Italy's preimplantation genetic testing market is valued at $8.9 million in 2025, with a projected CAGR of 9.8% through 2030, reaching $14.3 million by forecast end.

Fertility Clinic Adoption :

Italian fertility clinics are increasingly integrating advanced reproductive technologies, with heightened awareness among practitioners regarding the clinical and commercial benefits of genetic screening protocols.

Patient Awareness Expansion :

Growing patient education and acceptance of preimplantation genetic testing in Italy is driving demand, particularly among couples seeking to reduce genetic disorder risks and improve IVF success rates.

Regulatory Framework Support :

Italy's healthcare infrastructure and regulatory environment are progressively accommodating advanced genetic testing services, creating favorable conditions for market expansion and clinical implementation.

Italy Preimplantation Genetic Testing Market Dynamics

  • The 9.8% CAGR reflects growing confidence among Italian fertility centers in implementing PGT protocols and expanding service offerings to meet patient expectations for safer, more effective reproductive outcomes. The Italian market benefits from a mature healthcare system and growing awareness of genetic testing benefits among both medical professionals and patients.
  • As regulatory frameworks continue to evolve and reimbursement pathways become clearer, Italian fertility clinics are expected to accelerate PGT integration, supporting sustained market expansion through 2030..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Italy's PGT market is valued at $8.9 million in 2025 and will grow to $14.3 million by 2030, representing a 9.8% CAGR.
      • Italy's healthcare system increasingly integrates PGT into fertility clinics, driven by regulatory support and clinical adoption.
      • Rising patient awareness and demand for genetic disease prevention are key growth catalysts in Italy's reproductive medicine sector.
      • Italy's demographic challenges and aging population create sustained demand for advanced reproductive technologies including PGT.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      Italy Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES2.372.542.753.013.33.644.034.4710.2
      FERTILITY CLINICS6.767.217.768.449.2210.1211.1312.289.6
      HOSPITALS1.71.791.912.062.232.422.642.888.6
      OTHER END USERS0.660.690.730.780.840.910.991.077.9
      TOTAL11.4812.2313.1514.2915.617.0918.7820.79.5

      Target Audience

      • Fertility Clinic Operators : Italian fertility centers need market data to justify PGT service investments, benchmark against regional competitors, and plan clinical laboratory expansion aligned with projected patient demand growth.
      • Genetic Testing Laboratory Providers : Diagnostic and genetic testing companies require Italy-specific market intelligence to identify expansion opportunities, assess competitive positioning, and develop localized service offerings for Italian clinics.
      • Medical Device & Diagnostics Manufacturers : Equipment and reagent suppliers need Italy market insights to guide product development, distribution partnerships, and sales strategies targeting Italian fertility centers and diagnostic laboratories.
      • Healthcare Investment & Private Equity : Investors evaluating opportunities in Italian reproductive healthcare require validated market sizing, growth projections, and regulatory context to assess investment returns and portfolio company valuations.
      • Healthcare Policy & Regulatory Bodies : Italian health authorities and policy makers need market data to inform reimbursement decisions, regulatory frameworks, and healthcare resource allocation for genetic testing services in reproductive medicine.

      Key Companies in the Italy Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Italy-Specific Market Sizing : Access precise valuation data for Italy's PGT market with validated 2025 baseline ($8.9M) and 2030 forecast ($14.3M), enabling accurate financial planning and investment decisions for the Italian market.
      • Regional Growth Trajectory Analysis : Understand Italy's 9.8% CAGR performance relative to global 10.5% growth, identifying market dynamics unique to Italian fertility centers, regulatory environment, and patient demographics.
      • Fertility Clinic Expansion Strategy : Develop targeted service expansion plans for Italian fertility clinics by analyzing adoption rates, competitive positioning, and clinical integration opportunities specific to the Italian healthcare landscape.
      • Regulatory and Reimbursement Insights : Gain intelligence on Italy's healthcare infrastructure, regulatory framework, and emerging reimbursement pathways that directly impact PGT market accessibility and growth potential in the region.
      • Patient Demand Forecasting : Leverage Italy-specific awareness trends and patient acceptance data to forecast demand for genetic testing services, supporting marketing strategies and resource allocation for Italian market participants.

      Frequently asked questions

      What is the current market size of PGT in Italy?

      Italy's preimplantation genetic testing market was valued at $8.9 million in 2025 and is expected to grow to $14.3 million by 2030.

      What is the projected growth rate for Italy's PGT market?

      Italy's PGT market is projected to grow at a compound annual growth rate (CAGR) of 9.8% from 2025 to 2030.

      What factors are driving PGT adoption in Italy?

      Key drivers include rising patient awareness of genetic disease prevention, increased fertility clinic investment, regulatory support, and Italy's demographic pressures related to aging population and declining birth rates.

      How is Italy's PGT market positioned within Europe?

      Italy represents a significant European market for PGT, with steady growth driven by healthcare infrastructure development and increasing integration of genetic testing into assisted reproductive procedures.

      Which regions in Italy are leading PGT market growth?

      Major metropolitan areas and established fertility centers in northern and central Italy are driving market expansion through advanced reproductive technology adoption and clinical expertise.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status